Generated by AI
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs include late-stage and earlier-stage candidates built around its proprietary Antibody Biopolymer Conjugate platform, which is designed to support the development of next-generation eye medicines. Kodiak Sciences Inc. serves the biopharmaceutical and ophthalmic research markets by advancing specialized therapeutics for diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Headquartered in Palo Alto, California, and founded in 2009, the company remains focused on researching, developing, and commercializing retina-directed medicines for patients and eye-care specialists.
Website1250 Page Mill Road
Palo Alto, CA, 94304
United States
The latest articles about KOD.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about KOD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.